🏛️ Verified NIH Record • Updated 2026-06-16
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV (NCT04255849)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Weill Medical College of Cornell University
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult men living with HIV.
Who can join: Review the eligibility criteria below.
Location: Universidade de São Paulo — São Paulo, São Paulo
Age range: 20 Years to 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Universidade de São Paulo — São Paulo, São Paulo
- Instituto Nacional de Salud Pública, Mexico — Cuernavaca, Morelos
- University of Puerto Rico AIDS Clinical Trials Unit — San Juan, Purto Rico
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HPV Positive Oropharyngeal Squamous Cell Carcinoma
Explore by condition: All HPV Positive Oropharyngeal Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.